Moreover, Baselga et al. showed that treatment of exemestane plus the molecular-target drug, mTOR inhibitor, is very effective for the improvement of progression-free survival of advanced breast cancer after the failure of non-steroidal AI treatment [11]. Here, MTOR is linked to breast cancer.